Given aVNS can be implemented with minimally invasive approaches and has the potential to modulate vagal activity, there have been many early-stage clinical trials investigating a diverse range of potential therapeutic indications, including heart failure, epilepsy, depression, pre-diabetes, Parkinsons, and rheumatoid arthritis, and several aVNS devices were already developed for various applications (Verma et al
Preclinical studies have highlighted the broad therapeutic potential of AOCs
Support and Accountability: Participants receive ongoing support from a dedicated team of healthcare professionals
Convenience Tirzepatide is administered once weekly via a subcutaneous injection, making it a convenient option for patients who prefer less frequent dosing
2007, doi: 10.1016/j.phrs.2007.01.012
doi: 10.1016/j.micres.2021.126786 45 LingH.LiuR.SamQ